Janus Kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of Jak3 was associated with human hematologic and epithelial malignancies. Inhibitors of Jak3 have shown utility in many different disease such as autoimmune disorders, allograft rejection during transplantation, acute lymphoblastic leukemia, Type 1 diabetes, rheumatoid arthritis and allergy and asthma. Since these inhibitors make their way into clinical trials with profound effects, it is essential to develop a sensitive, precise, and rugged screening tool to screen synthetic compounds or other biomolecules that has the potential to modulate Jak3 functions and hence treat a wide variety of diseases. Present invention relates to novel high throughput system for finding previously unknown Jak3 interacting compounds, human biomolecule (e.g. proteins or others), and those compounds that can inhibit Jak3 activations. All these identified compounds and molecules can be used for the treatment of a wide variety of diseases (listed in table 1) where Jak3 activations or its interactions with other biomolecules are essential for disease sustenance or propagation in human body.